Researchers performed a randomized, placebo-controlled Phase II trial of men with localized prostate cancer and a rising prostate-specific antigen (PSA) level post-primary treatment. The men were randomized to receive Avodart (dutasteride @ 0.5 mg/day) or to receive a placebo. All of the men were receiving intermittent androgen deprivation therapy (IADT), which was stopped at month [...]
Many men with advanced prostate cancer who are on hormone therapy (ADT) use one of the newer drugs, degarelix (Firmagon) to achieve a state of castration. Degarelix is considered a superior drug for initiating ADT because it is not accompanied with a PSA flare that is common with the older luteinizing hormone-releasing hormone (LHRH) agonists [...]
As we all know there are now a number of new drugs available to treat castrate resistant metastatic prostate cancer (mCRPC). The availability of these new drugs (abiraterone acetate aka Zytiga, cabazitaxel aka Jevtana, and enzalutamide aka Xtandi) for use in men with mCRPC after the failure of chemotherapy (with docetaxel) has opened a number [...]
Cancer survivors have many additional problems in their life. I guess the most significant problem is that we have a life threatening illness. So, why are we forced to have to worry if our medications will be paid for or if we are able to afford to pay for them? When we are fighting for [...]
In a new study it was shown that smoking doubles the chances that a prostate cancer survivor will have the cancer spread and that he would die from the cancer. Study co-author Dr. Michael Zelefsky, Vice Chair of Clinical Research in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center said, "Basically we [...]